Institute Archive Header 1.png

Scroll for Details & Links Click for a Simple List of Recordings

Lab to market circle.png
  • Roundtable for Researchers

  • Translating Data Science

  • Intellectual Property

  • Commercialization

  • Investors Forum

  • Communicating Biomedical Research

  • Sustainability in the Lab

  • Emerging Technologies and Innovation

  • Consortium on Translational Research in the Microbiome

Building Biotech Circle.png
  • Westchester Biotech Blueprint 2030

  • Real Estate/Development Perspectives

  • Rare Disease Research Hub

  • Educators and Employers/Workforce Development

  • Young Investigators: Practical Guidance for Building Your Career

  • Virtual Executive in Residence Program

  • Government Relations

In addition to programs listed here, you can find recordings from our Symposia:
Innovation in Research 2019
Rare Disease Research Symposium 2018

Want to know more? Get In Touch!

Dot Green.png
Dot Yellow.png

Young Investigators - Lab to Market


Rigor and Reproducibility: Presenting Data to Funders and Investors
Rick Huntress, Director Business Development, Clinical/In Vivo Services, The Jackson Laboratory
More Information • RecordingPDF

Criteria that investors and companies use to evaluate drugs for licensing or acquisition can be different from those used by reviewers and journals for publication. In this webinar, we will discuss strategies that allow researchers to anticipate such concerns and generate the kind of data that investors appreciate.


Are You an Inventor, or Are You an Entrepreneur? 
Russell Thomas, Co-Founder and CEO, NIRvana Sciences
More Information • RecordingPDF

Starting a new life science company is not for the faint of heart. In this presentation, we explore the dimensions of personality and energies that are expressed in the lab and as the driver of business. Without judgement, we ask you to consider the anticipated journeys that can help you determine your approach to commercializing your breakthroughs.

commercialization july 25.jpg

Grant-Writing Essentials Series: Part 2 - The Commercialization Plan
Marla Coppolino, Director of BD and Outreach, Institute of Biotechnology, Cornell University
Douglas Greene, MD, Founder and Chief Consultant, DAGPHAMED
Dalfoni Banerjee, Principal Consultant & CEO, 3Sixty Pharma Solutions
More InformationRecordingPDF

The focus of this session is the all-important commercialization plan. Our experts share commercialization fundamentals to help you visualize the terrain that you will traverse as your product heads toward market and, potentially, patients.

Grant-Writing Essentials Series: Part 1 - NIH SBIR/STTR Grant-Writing Best Practices
Douglas Greene, MD, Founder and Chief Consultant, DAGPHAMED
Dalfoni Banerjee, Principal Consultant & CEO, 3Sixty Pharma Solutions
More InformationRecordingPDF

In this session, Dr. Doug Greene leads a discussion on how to “operationalize” the grant-writing process, enhancing the grant-writer’s prospect for success.

Establishing Your First Lab
Gregory Wiedman, Ph.D., Assistant Professor of Biochemistry, Seton Hall University
More InformationRecordingPDF

As a first time principal investigator (PI), the logistics of setting up your first lab can be daunting. From ordering equipment and supplies to recruiting the members who will work beside you, there are considerations to be made that most would not be immediately prepared for. We dive into these issues and more, focusing on preparing for your transition from a researcher to PI.

Leveraging Sustainability to Save Your Lab Budget
Erika Daley, Program Manager, My Green Lab
Stephen Harris, Ph.D., Assistant Professor of Biology, Purchase College, SUNY
More InformationRecordingPDF

Through the smart use of energy, water, reagents, and more, your lab can become more sustainable while simultaneously reducing operational costs. Practical steps to operate more sustainably in your lab right now are presented.

Shaping Drug Development Programs around Commercial Elements
Roland Turck, MD, Managing Partner, TurckBio
More Information • RecordingPDF

Dr. Turck will detail ways to incorporate commercial strategy into every stage of a life science product's development. He will discuss the market-to-product thought process required for a company and its intellectual property to realize their full potential. 

Bench to Bedside: Taking Research to the Market
Vinit Nijhawan, Managing Director, University Patent Monetization Program
UnitedLex and its subsidiary iRunway
More Information • RecordingPDF

Prior to UnitedLex Vinit was Managing Director, Office of Technology Development at Boston University where he launched 8 venture-backed spinoffs and successfully executed a patent monetization program.


From Lab to Market: An Intergenerational Discussion
Judith Sheft, Associate Vice President, Technology Development
New Jersey Institute of Technology
More Information • Recording

A collaboration between the Westchester Biotech Project (WBP), curiousSCIENCEwriters (cSw), and Young Women in Bio (YWIB), this session is designed to inspire high-school students interested in science to forge ahead towards their passion without concern.

Spark Talks.jpg

Nailing Your Spark Talk
Laura Green, Ph.D., Cancer Consortium Manager, Fred Hutchinson Cancer Research Center
More Information • RecordingPDF

Do you have a short, 1-3 minute talk to prepare?  Is your topic complex and seemingly hard to condense? Dipping your toes into the world of spark talks can be daunting without prior experience. This session aims to help early-career technologists prepare and plan for this popular form of science communication.


Science Communication: General Concepts and Tips
Laura Green, Ph.D., Cancer Consortium Manager, Fred Hutchinson Cancer Research Center
More Information • RecordingPDF

This session covers key practical approaches to considering your presentation audience, telling a compelling story of your research, effectively addressing questions, and developing powerful presentations to engage your audience.

Peer-to-Peer Communication
Laura Green, Ph.D., Cancer Consortium Manager, Fred Hutchinson Cancer Research Center
More Information • RecordingPDF

This session focuses upon effective communication with other scientists in symposia, lab meetings, seminars, and thesis defenses. Included are guidelines for effective presentations, slide preparation, and meaningful interaction with your audience.

IIR19 Group.jpg

Preparing for BIO
Dalfoni Banerjee, Principal Consultant & CEO, 3Sixty Pharma Solutions
Stephen Yelity, President & CEO, BusStim
More InformationRecordingPDF

It’s late to get started, but not too late to think about how you can find resources and potential partners at the big BIO conferences this year. You’ll hear about strategies you can enjoy now, and ideas to get you thinking about the future.

Dot Yellow.png

Rare Disease Research Hub

Rare Disease Update: Repurposing Drugs Through Computational Biology
Bruce Bloom, DDS, JD, CEO, Cures Within Reach
More Information • RecordingPDF

Exciting therapeutic potential in the repurposing of approved drugs is becoming a reality. Nowhere else does this practice have as much of a potential impact than in the treatment of rare diseases. Dr. Bloom discusses the benefits and challenges of drug repurposing, providing historical and contemporary successes with a focus on rare diseases.

Building the Rare Disease Research Community
Wendy Chung, MD, Ph.D., Kennedy Family Professor of Pediatrics and Medicine
Columbia University
More Information • RecordingPDF

Dr. Chung gives insights into her extensive work identifying new genes linked to rare diseases along with forefront approaches and challenges in the field. She discusses the rise and application of precision medicine techniques, generation of new data and research models, and the potential for genome-based targeting in advanced treatments.

Dot Green.png

Consortium on Translational Research in the Microbiome


Building Data Infrastructure for Microbiome Research
Jessica Dunne, Ph.D., Director, Discovery Research, JDRF
Robert McLaughlin, Ph.D., Vice President for Research, ILSE
More InformationRecordingPDF

Innovation is stunted if there is no framework that enables researchers to share and work on data in a structured, meaningful, and compatible way. The continued development of these types of data infrastructures will be key to accelerating innovation and fostering collaboration as the field of microbiome research becomes increasingly translational.


Standardization - Consortium on Translational Research in the Microbiome
Scott A. Jackson, Ph.D., Leader, Complex Microbial Systems Group, NIST
Dev Mittar, Ph.D., Lead Scientist, Microbiology R&D, ATCC
More Information • Recording

Appreciation for the role of microbes in our lives has been growing rapidly, but the measurement science needed to understand and fully exploit microbial systems has developed at a much slower pace than the industries dependent on them demand. Microbiome standards will support research investigations and commercial translation of microbiome science.


Reproducibility - Consortium on Translational Research in the Microbiome
Salomon Amar, D.D.S., Ph.D., Vice President for Biomedical Research, NYMC
Tasha Santiago-Rodriguez, Ph.D., Microbiome Discovery Analyst, Diversigen
More Information • RecordingPDF

Current challenges and opportunities in DNA extraction, reproducibility, and data analytics will be discussed. This ongoing Roundtable addresses data generation, collection, sequencing, analysis, and harmonizing systems to accelerate relevant, reproducible research.

Dot Green.png

Emerging Technologies and Innovation


International Perspectives on Value-Based Healthcare
Westchester Biotech Project Europe Launch Session
Jason Helgerson, Founder and Chief Solutions Officer, Helgerson Solutions Group
Vladimir Makarov, Consultant, Pistoia Alliance
Philippe Salphati, PharmD, Managing Director, France-Switzerland & Partner, Tefen Consulting
More InformationRecordingPDF

We discuss value-based healthcare and the potential it has to disrupt the international healthcare environment — creating value for patients, providers, and those involved along the way.

Building the Biotech Cluster, Innovation Cluster Development in a Dynamic Environment
Steve Wray, VP and Director, Regional Economics and Labor, Econsult Solutions
More Information • RecordingPDF

Cluster building is a multi-tiered, multi-year initiative, requiring the combined resources and collaborative efforts of numerous individuals and organizations. However, the resulting supportive life science infrastructure lays an enduring foundation for the future. In alignment with our mission, we look to other clusters for lessons learned during times of directed growth.

Practical Implications for AI and Machine Learning
Brian Hand, Partner, Nordlicht & Hand
More InformationRecordingPDF

Growth in the use of artificial intelligence and machine learning by life science companies and researchers will revolutionize the field of biotechnology. This webinar will examine the growth in the use of artificial intelligence, its impact on innovation as we move forward.


Emerging Technologies: Synthetic Biology, A Revolution Across All Industries
Karl Schmieder, CEO, messagingLAB
More InformationRecordingPDF

In this webinar we discuss the difference between biotechnology and synthetic biology, explore the impact synthetic biology is already having on business, and highlight how synthetic biology is evolving in New York State.

Dot Green.png

Translating Data Science

data science security.jpeg

Translating Data Science, Data Ownership and Security
Rebecca Herold, CEO, The Privacy Professor
Angela Radcliffe, R&D Practice Lead, Life Science, Capgemini Invent
More InformationRecordingPDF

As we continue forward in the age of digital information, the risks to personal privacy and security will only continue to increase. If we are to innovate, we must take great care to protect the individual along the way.


Translating Data Science, Addressing Interoperability
Hareesh Chandrupatla, Chief Data Scientist, Anjin Analytics
Angela Radcliffe, General Manager, Clinical Trial Solutions, PulsePoint
Kyle Gallatin, Data Scientist, Pfizer
Jabe Wilson, Consulting Director, Text and Data Analytics, Reed ElSevier
More InformationRecordingPDF

To address data interoperability and improved analytics, we bring together experts and thought leaders from industry, academia, and government for cross-silo collaboration.

data science 2.jpeg

Translating Data Science, Bias in Data Sets and Analytics
Scott Lett, Ph.D., Consulting Data Detective, Holistic Mathematics
Hareesh Chandrupatla, Chief Data Scientist, Anjin Analytics
Yacine Abdous, VP of Data Services, Cruz Street
Jim Duarte, Data Scientist/Consultant Advisor, Cruz Street
More InformationRecordingPDF

Ensuring the proper curation and integrity of data from the earliest stages of collection is absolutely essential.

Dot Green.png

Intellectual Property

To Share or Not to Share.png

To Share, or Not to Share? That is the Question
Scott D. Locke, Esq., Partner & Chair, Intellectual Property Department, Dorf & Nelson
Ayorinde Hassan, Ph.D., Intellectual Property, Business Development Executive, IBM Research
More Information • RecordingPDF

In this session, we cover the things companies and entrepreneurs fear most about sharing their ideas. Speakers will address which aspects of your intellectual property you should or should not share with others, discussing how to maintain good collaboration and communication while limiting issues that could pose problems for your company or idea.

IP digital.jpeg

Intellectual Property Issues for Bioinformatics and Digital Innovation 
Scott D. Locke, Esq., Partner & Chair, Intellectual Property Department, Dorf & Nelson
Laura Smalley, Esq., Member, Harris Beach
More Information • RecordingPDF

Among the most rapidly growing sub-disciplines in the biotechnology industry are the management and manipulation of data, the creation of code for bioinformatics, and personalization of medicine, and the creation of apps. Insights into the patenting guidelines surrounding these digital innovations are shared.


Intellectual Property: Timing is Everything 
Scott D. Locke, Esq., Partner & Chair, Intellectual Property Department, Dorf & Nelson
More Information • RecordingPDF

When it comes to developing a patent protection strategy there are many issues to consider. One of the most critical of these issues is determining when, during the innovation process, the right time to file for patent protection is. Expert advice in identifying that time is crucial to realizing your full market potential.

Dot Yellow.png

Government Relations


Implementing Volume to Value Initiatives, Advocacy for Community Health Centers
Andrea Ruggiero, Vice President of Community Health, Open Door Family Medical Centers
Matthew McLarnon, Government Relations and Policy Associate, Capital Health Consulting
More Information • RecordingPDF

We explore the social determinants of community health, discussing the opportunities and challenges inherent to improving the wellbeing of our communities. Speakers will cover innovative responses to social challenges, and highlight the need for advocacy by teams and members of the community.


Government Relations Midterm Update, Outlook for 2019
Lisa Wickens-Alteri, President, Capital Health Consulting
Matthew McLarnon, Government Relations and Policy Associate, Capital Health Consulting
Andrew Zebrak, Executive Director, Public Policy and Advocacy, Boehringer Ingelheim
More Information • RecordingPDF

After the midterms, what changes in policy may be on the horizon and how will we best navigate them? Experts from our Advisory Board will update us on state and federal life science policy moving forward, anticipating challenges to prepare for and identifying opportunities to support.

govt relations.jpeg

Making a Difference Through Smart Government Relations
Lisa Wickens-Alteri, President, Capital Health Consulting
Matthew McLarnon, Government Relations and Policy Associate, Capital Health Consulting
More Information • RecordingPDF

Over 47 companies have launched in New York State over the last three decades, placing NY in the #2 spot in the nation for funding biotech and life science research and development. Even with the positive influx of investment and the establishment of science as a public authority in New York, the industry is still confronted by governmental barriers and bureaucratic policy.

ESD webinar.jpeg

Incentives for New York State Life Science Companies
Loretta Beine, Life Science Industry Development Director, Empire State Development (ESD)
More Information • RecordingPDF

Life Science companies, along with their suppliers and partners, can benefit from a range of New York state incentives, including a new R&D tax credit progam. These programs encourage business investment and job creation, supporting diverse, prosperous local economies across New York State.


Whats Missing?

We accept Abstracts throughout the year.
Send a note to with “Webinar Abstract” in the title.